Time Is Running Out For Revised EU Clinical Trials Legislation
This article was originally published in The Pink Sheet Daily
A compromise has not been reached yet by EU stakeholders on the new Clinical Trials Directive, but unless one emerges soon, the legislation will be dead.
You may also be interested in...
John Dalli has resigned following allegations of fraud, bringing to an end a successful, but controversial career, and leaving the future of a number of legislative programs he championed – including anti-counterfeiting, risk assessments and biosimilar reviews – up in the air.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.